Adma Biologics, Inc. (ADMA)

Trade ADMA now with
1/7/2019 7:20:55 AM ADMA Biologics Submits Response And Provides Supplemental Information To FDA For BIVIGAM CRL
12/17/2018 7:02:43 AM WBB Securities Starts ADMA BIOLOGICS, INC. (ADMA) At Speculative Buy With $9 Price Target
10/17/2018 7:09:20 AM ADMA Biologics Receives PDUFA Date Of April 2, 2019 For RI-002
10/11/2018 8:49:31 AM ADMA Biologics Provides Regulatory Update For BIVIGAM
10/3/2018 7:12:29 AM ADMA BioCenters Gets FDA Approval For Third Plasma Collection Center
10/1/2018 7:09:15 AM ADMA Biologics Resubmits BLA For RI-002
9/5/2018 8:11:30 AM LabConnect Appoints Eric Richman As Chairman
9/5/2018 7:09:03 AM ADMA Biologics Reports FDA Inspection Database Confirms VAI Status Of Boca Raton, FL Facility
8/10/2018 7:10:01 AM ADMA Biologics Q2 Net Loss $14.7 Mln Or $0.35/Shr Vs Loss Of $9.0 Mln Or $0.55/Shr Last Year
7/26/2018 7:59:48 AM ADMA Biologics Gets PDUFA Date For BIVIGAM Regulatory Submission; Target Action Date For PAS Is Oct. 25, 2018
6/12/2018 4:08:52 PM ADMA Biologics Closes $40 Mln Public Offering
6/8/2018 9:10:01 AM ADMA Biologics Prices Public Offering Of 8.37 Mln Shares At $4.78/Shr
6/7/2018 4:11:33 PM ADMA Biologics Announces Proposed Public Offering Of Common Stock
5/16/2018 7:32:20 AM ADMA Biologics Granted U.S. Patent For Treating Respiratory Infections